Skip to main content
Premium Trial:

Request an Annual Quote

Illumina, Mayo Clinic to Co-Develop Molecular Diagnostics

NEW YORK (GenomeWeb News) — Illumina and the Mayo Clinic today said they plan to co-develop molecular diagnostics for certain undisclosed diseases, Illumina said today.
Under the agreement, Illumina will provide its VeraCode technology and its know-how on the BeadArray platform to Mayo Medical Laboratories, which have had the technology since January 2005.
Mayo Labs will use the systems to discover and validate biomarkers offering the “potential for both parties to implement important new clinical tests,” Illumina said.  
Illumina will then make and market tests worldwide on its BeadArray and upcoming BeadXpress reader using biomarkers or other IP Mayo develops, the company said.  
“Expanding our relationship with Mayo Clinic … represents an important step in the revolution of our diagnostics strategy,” said Jorge Velarde, Illumina’s senior director of business development.  
Financial terms of the agreement were not released.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.